Journal
LANCET ONCOLOGY
Volume 12, Issue 12, Pages 1169-1174Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(11)70123-1
Keywords
-
Categories
Funding
- Cancer Research UK [15601] Funding Source: Medline
- Cancer Research UK [15601] Funding Source: researchfish
Ask authors/readers for more resources
High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available